乳腺水肿评分作为肿瘤侵袭性生物标志物及其对新辅助化疗反应的预测价值
本回顾性研究纳入235例经活检证实的浸润性乳腺癌女性患者,分析新辅助化疗前乳腺MRI的乳腺水肿评分(BES)与肿瘤侵袭性及病理反应的关系。结果显示BES与较大肿瘤尺寸、较高组织学分级、腋窝淋巴结转移、激素受体阴性、淋巴血管侵犯及Ki-67升高相关,但水肿或BES均不能预测新辅助化疗的病理反应。
要点
- BES与较大肿瘤尺寸、较高组织学分级、激素受体阴性等侵袭性特征相关。
- BES2-4组与肿瘤尺寸、分级、激素受体阴性、非管腔亚型及瘤内坏死有更强关联。
- 水肿或BES均不能预测新辅助化疗的病理反应(p=0.999,p=0.299)。
核心结论
- BES和水肿是肿瘤侵袭性的稳健影像生物标志物,但对新辅助化疗反应无预测价值。
研究设计与样本
- 回顾性研究,235例经活检证实的浸润性乳腺癌女性患者(平均年龄52±12岁)接受新辅助化疗前乳腺MRI,排除19例(10例图像质量不足,9例活检后成像)后分析216例。
关键影像表现/征象
- 水肿存在与较大肿瘤尺寸(p=0.001)、较高组织学分级(p=0.001)、腋窝淋巴结转移(p=0.015)、激素受体阴性(p<0.001)、淋巴血管侵犯(p=0.031)及Ki-67升高(p=0.001)显著相关。
- 较高BES组(BES2-4)与侵袭性特征有更强关联:肿瘤尺寸(p<0.001)、分级(p=0.022)、激素受体阴性(p=0.001)、非管腔亚型(p=0.001)及瘤内坏死(p=0.002)。
诊断标准与关键数值
- BES分类的观察者间一致性非常高(92.6%符合率)。
- 水肿或BES均不能预测新辅助化疗的病理反应(p=0.999,p=0.299)。
临床应用与阅片要点
- BES可作为非侵入性肿瘤表型和风险分层的实用影像生物标志物。
- BES在预测新辅助化疗反应方面无实用性,强调治疗计划中需要补充预测工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate MRI-based breast edema patterns as biomarkers of tumor aggressiveness and their predictive value for pathological response to neoadjuvant chemotherapy (NAC) in invasive breast cancer.
MATERIALS AND METHODS: This retrospective study evaluated 235 female patients (mean age, 52 ± 12 years) with biopsy-proven invasive breast cancer who underwent pre-NAC breast MRI. After excluding 19 patients (10 for inadequate image quality, 9 for post-biopsy imaging), 216 patients were analyzed. Breast edema score (BES) was independently assessed by two radiology residents to evaluate interobserver agreement. Subsequently, a breast radiologist reviewed all cases to establish the definitive dataset. The differences in clinicopathological characteristics between the two groups and between different BES were compared.
RESULTS: Interobserver agreement for BES classification was very high (92.6% concordance). Edema presence correlated significantly with larger tumor size (p = 0.001), higher histological grade (p = 0.001), axillary lymph node metastasis (p = 0.015), hormone receptor negativity (p < 0.001), lymphovascular invasion (p = 0.031), and elevated Ki-67 (p = 0.001). Higher BES groups (BES 2-4) showed stronger associations with aggressive features: tumor size (p < 0.001), grade (p = 0.022), hormone receptor negativity (p = 0.001), non-luminal subtypes (p = 0.001), and intratumoral necrosis (p = 0.002). Neither edema nor BES predicted pathological response to NAC (p = 0.999, p = 0.299).
CONCLUSION: BES and edema are robust imaging biomarkers of tumor aggressiveness but demonstrate no predictive value for NAC response. MRI-based edema scoring holds clinical relevance for noninvasive tumor phenotyping and risk stratification in breast cancer management.
KEY POINTS: Question Can MRI-based breast edema patterns predict tumor aggressiveness and pathological response to neoadjuvant chemotherapy in invasive breast cancer patients, aiding noninvasive risk stratification? Findings BES correlates with aggressive tumor features (larger size, higher grade, hormone negativity; all p < 0.050 but shows no predictive value for NAC response (p = 0.299). Clinical relevance BES serves as a practical imaging biomarker for risk stratification and tumor phenotyping, guiding individualized therapy. However, it shows no utility in predicting NAC response, emphasizing the need for complementary predictive tools in treatment planning.
引用
- Onar MA, Jabbarlı E, Polat AV, et al. Breast edema score as a biomarker of tumor aggressiveness and its predictive value for neoadjuvant chemotherapy response. Eur Radiol. 2026. PMID: 41803553. doi:10.1007/s00330-026-12406-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。